Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Pharmaceuticals Inc.

Division of Endo International PLC
www.endo.com/endopharma/home

Latest From Symetis SA

EuroPCR 2017: TAVR Continues To Beat Surgery; Bioabsorbable Stents Not Going Away

The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.

Cardiology Clinical Trials

EuroPCR 2017: Boston Scientific's Lotus TAVR Beats Medtronic's CoreValve In REPRISE III, But Pacemaker Issue Remains

Boston Scientific's repositionable, mechanically expanded Lotus transcatheter aortic valve performed better than Medtronic's CoreValve for the primary composite effectiveness endpoint in the REPRISE III trial, according to results presented at the EuroPCR meeting in Paris. But the Lotus patients in the trial were more likely to need a pacemaker than the CoreValve patients, a risk that investigators believe can be mitigated with better operator technique.

Cardiology Clinical Trials

Symetis TAVR Buy Not About Throwing Shade On Lotus, BSX Insists

Europe's No. 3 in the transcatheter aortic valve replacement market, Boston Scientific, has inked a $435m deal to acquire its smaller Swiss rival Symetis. The US company bats away skeptics wondering whether the transaction signals Boston Scientific's shaky faith in its own Lotus valve platform, which is currently subject of a major recall. One casualty of the acquisition will be early-stage mitral valve technology company Middle Peak Medical, which Symetis had only bought a month ago.

Cardiology M & A

Symetis Seeks $60m IPO To Make A Splash In Structural Heart

Symetis, Europe's No. 4 in the TAVR market, hopes its initial public offering, with a price range of €26 to €32 per share on Euronext Paris, will help build on its recent transcatheter mitral valve repair acquisition and its growing market position in TAVR.

Cardiology Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endo International PLC
  • Senior Management
  • Contact Info
  • Endo Pharmaceuticals Inc.
    Phone: (484) 216-0000
    1400 Atwater Dr.
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register